Annalisa Pappalardo
Overview
Explore the profile of Annalisa Pappalardo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
168
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Giunta E, Arrichiello G, Pappalardo A, Federico P, Petrillo A
Cancer Treat Res
. 2024 Jan;
188:89-104.
PMID: 38175343
The occurrence of gastric cancer has been associated with an increased risk of lobular breast tumors in a subset of patients harboring selected germline mutations. Among all, the germline alteration...
2.
Ferriero M, Prata F, Anceschi U, Astore S, Bove A, Brassetti A, et al.
Cancers (Basel)
. 2023 Oct;
15(19).
PMID: 37835503
Registrative trials recommended the use of upfront chemotherapy in high-volume metastatic prostate cancer. We reported survival outcomes of patients with high-volume mCRPC treated with ARTA in a chemo-naïve setting compared...
3.
Nevola R, Rosato V, Conturso V, Perillo P, Le Pera T, Del Vecchio F, et al.
Biology (Basel)
. 2022 Jun;
11(6).
PMID: 35741326
People who use drugs (PWUDs) are a crucial population in the global fight against viral hepatitis. The difficulties in linkage to care, the low adherence to therapy, the frequent loss...
4.
Rosato V, Nevola R, Conturso V, Perillo P, Mastrocinque D, Pappalardo A, et al.
Biology (Basel)
. 2022 Jun;
11(6).
PMID: 35741321
People who use drugs (PWUDs) are generally considered "hard-to-treat" patients, due to adherence to HCV antiviral therapy or re-infection concerns. Linkage-to-care still remains a significant gap for HCV elimination, worsened...
5.
Pappalardo A, Giunta E, Tirino G, Pompella L, Federico P, Daniele B, et al.
Front Oncol
. 2021 Sep;
11:695627.
PMID: 34485130
Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease even in the early stages, despite progresses in surgical and pharmacological treatment in recent years. High potential for metastases is the main...
6.
Giunta E, Arrichiello G, Curvietto M, Pappalardo A, Bosso D, Rosanova M, et al.
Cells
. 2021 Aug;
10(8).
PMID: 34440824
Cutaneous melanoma is a lethal disease, even when diagnosed in advanced stages. Although recent progress in biology and treatment has dramatically improved survival rates, new therapeutic approaches are still needed....
7.
Petrillo A, Giunta E, Pappalardo A, Bosso D, Attademo L, Cardalesi C, et al.
J Clin Med
. 2021 Apr;
10(8).
PMID: 33921760
Gastric cancer (GC) is the third cause of cancer-related death worldwide; the prognosis is poor especially in the case of metastatic disease. Liver, lymph nodes, peritoneum, and lung are the...
8.
Federico P, Giunta E, Pappalardo A, Tufo A, Marte G, Attademo L, et al.
Pharmaceuticals (Basel)
. 2021 Apr;
14(3).
PMID: 33800217
Hepatocellular carcinoma (HCC) is the primary tumour of the liver with the greatest incidence, particularly in the elderly. Additionally, improvements in the treatments for chronic liver diseases have increased the...
9.
Pompella L, Tirino G, Pappalardo A, Caterino M, Ventriglia A, Nacca V, et al.
Int J Mol Sci
. 2020 Apr;
21(8).
PMID: 32316602
Pancreatic cancer represents one of the most lethal disease worldwide but still orphan of a molecularly driven therapeutic approach, although many genomic and transcriptomic classifications have been proposed over the...
10.
Tirino G, Petrillo A, Pompella L, Pappalardo A, Laterza M, Panarese I, et al.
Front Oncol
. 2020 Mar;
10:130.
PMID: 32128313
The prognosis of patients with advanced gastric cancer remains overall poor despite some recent innovations and the development of new therapeutic approaches. Current European guidelines do not recommend any specific...